Hem/Onc Roundup: Chemicals in Tap Water Linked to Cancer, Biosimilars Drive Down Biologic Costs, and more

Here are the top stories covered by DocWire News this week in the Hematology & Oncology section. This week, the U.S. Food and Drug Administration (FDA) issued a warning about weight management drugs and a cancer link, 9/11 first responders face an increased risk of certain cancer, and more.

A study published in JNCI Cancer Spectrum observed an increased risk of prostate cancer, thyroid cancer, and leukemia in 9/11 first responders.

The FDA issued a warning that the weight management drugs Belviq® and Belviq XR® (lorcaserin) may increase the risk of cancer.

Exposure to trihalomethanes found in tap water increases the risk of bladder cancer and may be responsible for one in 20 bladder cancer cases in the European Union, according to a study published in Environmental Health Perspectives.

The net prices of biologic agents have decreased following the introduction of biosimilar or other alternatives, according to a study published in JAMA Network Open.

In case you missed it, more hem/onc headlines are featured below:

• Cancer Survivors, Especially Younger Ones, Frequently Face Medical Financial Hardship and Financial Sacrifices
• New Research Suggests Lactate May Prompt Mutated Cells to Become Cancerous
• Progression-free Survival is Not a Valid Surrogate Endpoint for Overall Survival in First-Line Advanced Ovarian Cancer Treatment
• Recurrence Score May Predict Locoregional Recurrence in Breast Cancer